

INFORMATION DISCLOSURE STATEMENT


Applicant : Balzarini et al.
App. No : 10/783,053
Filed : February 19, 2004
For : IDENTIFICATION OF COMPOUNDS
THAT INHIBIT REPLICATION OF
HUMAN IMMUNODEFICIENCY
VIRUS
Examiner : Not Yet Assigned
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 24, 2006

(Date)


Eric S. Furman, Reg. No. 45,664**Mail Stop Amendment**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing (15) references to be considered by the Examiner. Also enclosed are (10) references including a copy of the Partial International Search Report and/or non-patent literature as listed on the Information Disclosure Statement.


This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 24, 2006By: 

Eric S. Furman
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT**


Applicant : Balzarini et al.
App. No : 10/783,053
Filed : February 19, 2004
For : IDENTIFICATION OF COMPOUNDS
THAT INHIBIT REPLICATION OF
HUMAN IMMUNODEFICIENCY VIRUS
Examiner : Not Yet Assigned
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 24, 2006

(Date)


Eric S. Furman, Reg. No. 45,664

Mail Stop Amendment

Commissioner for Patents


P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing (15) references.
 - (X) Enclosing (10) references including a copy of the Partial International Search Report.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/783,053
Filing Date	February 19, 2004
First Named Inventor	Jan Maria Balzarini
Art Unit	1648
Examiner	Emily Le
Attorney Docket No.	TRIPEP.058A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,833,148	05-23-1989	Olney et al.	
	2	4,588,729	05-13-1986	Teranishi et al.	
	3	3,502,471	03-24-1970	Van Pee et al.	
	4	2005/0096319 A1	05-05-2005	Balzarini et al.	
	5	2004/0180893 A1	09-16-2004	Balzarini et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	6	DE 2003 994 A1	07-30-1970	Eli Lilly and Company		
	7	WO 97/32855 A	09-12-1997	American Home Products Corporation		
	8	EP 0 540 143 A2	05-05-1993	Medivir Aktiebolag		
	9	WO 2004/073703 A1	09-02-2004	Tripep AB		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	10	Abdel-Rahman R.M., "Synthesis and Anti-Human Immune Virus Activity of Some New Fluorine Containing Substituted 3 Thioxo-1, 2, 4-Triazin-5-Ones," Farmaco (Rome), vol. 46, no. 2, 1991, pages 379-390.	
	11	Abdel-Rahman R.M., "Role of uncondensed 1,2, 4-Triazine Compounds and Related Heterobicyclic Systems as Therapeutic Agents - A Review," Pharmazie, vol. 56, no. 1, January 2001, pages 18-22.	
	12	Kuo, Chih-Ling, et al., "Application of CoMFA and CoMSIA 3D-QSAR and Docking Studies in Optimization of Mercaptobenzenesulfonamides as HIV-1 Integrase Inhibitors," Journal of Medicinal Chemistry, January 15, 2004, vol. 47, no. 2, pages 385-399.	
	13	Morsey, J.M. et al., "Synthesis of 1,2,4-Triazino [5,6-b] Indoles Bearing 1,2,4-Triazine Moiety," Bollettino Chimico Farmaceutico, March-April 2001, vol. 140, no. 2, pages 83-89.	
	14	Zhu X. et al., "Thiothalidomides: Novel Isoteric Analogues of Thalidomide with Enhanced TNF- α Inhibitory Activity," Journal of Medicinal Chemistry, American Chemical Society, vol. 46, no. 24, October 16, 2003, pages 5222-5229.	
	15	Communication Relating to the Results of the Partial International Search for International Patent Application No. PCT/IB2005/003755 filed August 16, 2005.	

2773159
072106

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.